Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of Switching from Oral to Transdermal Rivastigmine in Alzheimer's Dementia
NCT01585272Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2012
- Primary completion
- Jun 2015
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoint: Number of Patients With Adverse Events, Serious Adverse Events, and Death. Started Aug 2012; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01585272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585272.